ライフサイエンスコーパス: calcitriol

1 abolite of vitamin D(3), into 1,25(OH)2D(3) (calcitriol).

2 to its DNA target sequences was enhanced by calcitriol.

3 the only miRNA significantly up-regulated by calcitriol.

4 scription in the nanomolar range, similar to calcitriol.

5 and neonate without relying on vitamin D or calcitriol.

6 ecomes more severe, limiting the efficacy of calcitriol.

7 corrected with phosphate supplementation and calcitriol.

8 fore influences the efficacy of therapy with calcitriol.

9 vitamin D receptor only about 1% as well as calcitriol.

10 sed to assess the antiangiogenic activity of calcitriol.

11 mall interfering RNA restored sensitivity to calcitriol.

12 rentiation and transcriptional activity than calcitriol.

13 be significant bone loss after discontinuing calcitriol.

14 tor but declined with daily and intermittent calcitriol.

15 ed media of prostate cancer cells exposed to calcitriol.

16 d, although these changes were attenuated by calcitriol.

17 ate width did not increase with either GH or calcitriol.

18 nt survival advantage over those who receive calcitriol.

19 cells and makes T cells highly sensitive to calcitriol.

20 Very low doses of calcitriol (0.1-1 mug/kg body weight) were sufficient to

21 h quarterly 2 mg IBN intravenously and daily calcitriol (0.25-1.0 mug) on top of 1000 mg calcium and

22 eceive either alendronate (10 mg per day) or calcitriol (0.5 microg per day) a mean (+/-SD) of 21+/-1

23 itamin D3 (vitD3) and its active metabolite, calcitriol (1,25-(OH)(2)D(3)), affect multiple tissue ty

24 Calcitriol (1,25-dihydroxycholecalciferol), the major ac

25 Calcitriol (1,25-dihydroxycholecalciferol), the most act

26 s to evaluate the antiangiogenic activity of calcitriol (1,25-dihydroxyvitamin D(3)) in vivo and its

27 Oral calcitriol (1,25-dihydroxyvitamin D(3)) prevented as wel

28 olr1 KO mice with the VDR activating ligand, calcitriol (1,25-dihydroxyvitamin D(3)), resulted in ove

29 Exogenous calcitriol (1,25-dihydroxyvitamin D) and high circulatin

30 In all, 75 subjects (34 alendronate, 25 calcitriol, 16 reference) participated.

31 The A-rings of calcitriol (1alpha,25-dihydroxyvitamin D(3)) and 1alpha-

32 ntigen chromogranin A (ChgA) with or without calcitriol (1alpha,25-dihydroxyvitamin D3) into liposome

33 Calcitriol (1alpha,25-dihydroxyvitamin D3) is the active

34 We investigated the effects of calcitriol (1alpha,25-dihydroxyvitamin D3; the active fo

35 Furthermore, ingestion of calcitriol (1alpha25VitD3) by human volunteers led to an

36 were randomized to receive a single dose of calcitriol (2 mug intravenously) versus placebo.

37 study demonstrates that upon treatment with calcitriol, 24-hydroxylase (CYP24) mRNA, protein and enz

38 lcium (1200 mg/d), magnesium (550 mg/d), and calcitriol (25 mug/d) given either RCE (60 mg isoflavone

39 re measured through thin and thick layers of calcitriol 3 microg per g ointment and vehicle.

40 tment with paricalcitol (29,021 patients) or calcitriol (38,378 patients) between 1999 and 2001.

41 re assigned randomly to groups given 0.5 mug calcitriol, 75 mg acetylsalicylic acid, and 1250 mg calc

42 to 1alpha,25-dihydroxyvitamin D3 (1,25-D3 or calcitriol), a naturally occurring VDR agonist, VDR 4-1

43 Calcitriol, a regulator of calcium homeostasis with anti

44 Calcitriol, acting through vitamin D receptors (VDR) in

45 gical actions constitutes a novel pathway of calcitriol action that may contribute to its antiprolife

46 we present evidence that vitamin D hormone (calcitriol) activates the transcription of the serotonin

47 Thus, we investigated the role of calcitriol (active metabolite of vitamin D) in the regul

48 oidal analogues have been developed to mimic calcitriol activity profiles with low calcium serum leve

49 Calcitriol administration did not increase plasma cathel

50 Although no deaths occurred, calcitriol administration was associated with increased

51 ol but were slightly diminished during daily calcitriol administration.

52 In addition, calcitriol allows for the up-regulation of the recently

53 In these experiments, calcitriol alone had no effect on the HCV life cycle.

54 Calcitriol also augmented the angiogenic capacity of MAC

55 Calcitriol also repressed the mRNA expression of the PG

56 Calcitriol also up-regulated the expression of 15-hydrox

57 Since the calcitriol analogue 12 was prone to conversion into its

58 signed and synthesized novel C-9 substituted calcitriol analogues, possessing different nonpolar grou

59 l death was significantly different for both calcitriol and 16,23-D(3) compared with control tumors a

60 synthesized two gemini which are related to calcitriol and 19-norcalcitriol containing two identical

61 d analogs are as transcriptionally active as calcitriol and are strongly antiproliferative in vitro b

62 ry low postoperative PTH levels require oral calcitriol and calcium supplementation.

63 t1, which was released upon stimulation with calcitriol and IFN-alpha.

64 We propose that a combination of calcitriol and nonselective NSAIDs might be a useful che

65 ude that low, clinically relevant dosages of calcitriol and paricalcitol may protect against CKD-stim

66 we studied the effects of the VDR activators calcitriol and paricalcitol on aortic calcification in a

67 plicated by the adynamic bone disorder; both calcitriol and paricalcitol stimulated osteoblast surfac

68 nt to correct secondary hyperparathyroidism, calcitriol and paricalcitol were protective against aort

69 te a small therapeutic effect of calcium and calcitriol and suggest that tacrolimus is less osteotoxi

70 When Th9 cells are treated with both calcitriol and trichostatin A (histone deacetylase inhib

71 c ultraviolet modalities on the stability of calcitriol and, conversely, to study the effects of calc

72 mbination of acetylsalicylic acid (aspirin), calcitriol, and calcium carbonate could prevent colorect

73 atients were cultured with and without 10 nM calcitriol, and function determined by migration and ang

74 leted the randomized trial on alendronate or calcitriol, and in reference subjects who had received n

75 an associated increase in FGF23, decrease in calcitriol, and no change in phosphorus.

76 es, 25(OH)D, parathyroid hormone, estradiol, calcitriol, and urinary calcium at baseline and 6 wk in

77 Thus, calcitriol appears to suppress autoimmunity by inhibitin

78 These actions of calcitriol are mediated at least in part by vitamin D re

79 s, such as TNF-alpha, IFN-gamma, and LPS, or calcitriol, are not effective.

80 trials investigating the dose and timing of calcitriol as a therapeutic agent in specific sepsis phe

81 In a prospective study, the combination of calcitriol, aspirin, and calcium carbonate did not preve

82 Calcitriol attenuated specific histone acetylation at th

83 hibition, which did not result from elevated calcitriol bioavailability due to ITZ-mediated 24-hydrox

84 In summary, we have identified that calcitriol blocked the access of PU.1 to the Il9 gene by

85 Active VitD (calcitriol) blocked LEC tube formation, reduced LEC prol

86 After discontinuing alendronate or calcitriol, BMD remained stable during the second year a

87 -fed control group and the CKD low-phosphate/calcitriol/BMP-7 groups had reduced phosphate levels com

88 increased with GH alone or with intermittent calcitriol but were slightly diminished during daily cal

89 )D3 were independent predictors of decreased calcitriol, but the effects on calcitriol levels of rena

90 The endogenous production of calcitriol by monophosphoryl lipid A-stimulated DCs appe

91 suggesting that excessive overproduction of calcitriol by this neuroendocrine tumor was the cause of

92 ral hormone 1alpha,25-dihydroxyvitamin D(3) (calcitriol) by a 1alpha-CHF(2) group and incorporating a

93 yvitamin D) is converted to the active form (calcitriol) by the hydroxylase enzyme CYP27B1 In multipl

94 FGF-23, PTH, 25(OH)D3, calcitriol, calcium, phosphate, and urinary fractional e

95 ion that the intracellular concentrations of calcitriol can play an important role in either promotin

96 Oral calcitriol, compared with placebo, therapy of the patien

97 Finally, supernatants of calcitriol-conditioned bone marrow-derived DC had reduce

98 Calcitriol (CTR) administration prevented a decrease in

99 per d (Nx-Phos+GH; n = 9), (3) GH and daily calcitriol (D) at 50 ng/kg per d (Nx-Phos+GH+daily D; n

100 in the face of advancing CKD but may worsen calcitriol deficiency and thus may be a central factor i

101 23) associated with kidney injury results in calcitriol deficiency, altered calcium homeostasis, and

102 Hyperphosphatemia, calcitriol deficiency, and secondary hyperparathyroidism

103 eased fractional excretion of phosphate, and calcitriol deficiency.

104 ssociated with serum phosphate, Fe(PO4), and calcitriol deficiency.

105 preclinical proof of concept, we showed that calcitriol, delivered topically or intraperitoneally, in

106 It was shown that gemini, the calcitriol derivative containing two side chain at C20,

107 Moreover calcitriol or calcitriol derivatives combined with ITZ might be a trea

108 DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel wi

109 In vitro, calcitriol directly suppressed IL-17 induction in purifi

110 vels, cinacalcet use, or phosphate binder or calcitriol dose in either study arm.

111 Calcitriol downregulated MerTK mRNA and protein expressi

112 found that pretreatment with Dex potentiates calcitriol effects by inhibiting cell growth and increas

113 To investigate the role of VDR in calcitriol effects on tumor vasculature, we established

114 However, calcitriol enhanced the inhibitory effect of IFN-alpha o

115 In contrast, calcitriol enhanced the recruitment of the histone modif

116 criptional potency almost as high as that of calcitriol, even though it binds to the human vitamin D

117 Calcitriol exhibits antiproliferative and pro-differenti

118 of 42 strata examined, and in no stratum was calcitriol favored.

119 The sham-operated low-phosphate/calcitriol-fed control group and the CKD low-phosphate/c

120 cipants in a trial comparing alendronate and calcitriol for prevention of posttransplant osteoporosis

121 randomized trial comparing alendronate with calcitriol for the prevention of bone loss during the fi

122 ibits 1,25-dihydroxyvitamin D3 (1,25(OH)2D3; calcitriol) formation and phosphate reabsorption in the

123 cells in the presence of TNF-alpha generated calcitriol from 25-hydroxyvitamin D, resulting in repres

124 E production and that B cells can synthesize calcitriol from its precursor 25-hydroxyvitamin D3 (inac

125 hat Ptch expression is sufficient to release calcitriol from the cell and that calcitriol inhibits Sm

126 ol was administered in the CKD low-phosphate/calcitriol group (ABD), Ca, PO(4), and parathyroid hormo

127 ne formation marker, increased by 54% in the calcitriol group (P< or =0.001) and by 32% in the alendr

128 ker, serum N-telopeptide, rose by 27% in the calcitriol group (P< or =0.001).

129 h 8.2 and 13.9 percent, respectively, in the calcitriol group (P<0.001).

130 the alendronate group and 1.6 percent in the calcitriol group (P=0.25 for the test of no difference).

131 the alendronate group and 2.1 percent in the calcitriol group (P=0.69).

132 veloped in 27 percent of the patients in the calcitriol group and 7 percent of those in the alendrona

133 te group; P=0.15 for the comparison with the calcitriol group), and the mean density at the femoral n

134 in the alendronate group, 3.6 percent in the calcitriol group, and 13.6 percent in the reference grou

135 biochemical marker of bone resorption in the calcitriol group.

136 f CYP24, which led to loss of sensitivity to calcitriol growth inhibitory effects.

137 rgeted therapies under investigation include calcitriol, growth factor-targeted agents, epothilones a

138 Calcitriol had no effect on clinical outcomes nor were a

139 itamin D(3) and 1, 25-dihydroxyviatmin-D(3) (calcitriol) had beneficial effects in EAE/MS.

140 We conclude that endogenous calcitriol has an impact on the regulation of IgE in viv

141 Vitamin D and calcium are ineffective, but calcitriol has utility in some reports.

142 form of vitamin D, 1,25-dihydroxyvitamin D3 (calcitriol), has a profound inhibitory effect on the dev

143 argylic ether analogs of the natural hormone calcitriol have been rationally designed and easily synt

144 d that subjects randomized to alendronate or calcitriol immediately after cardiac transplantation sus

145 In this small experimental study, calcitriol improved endothelial function in patients wit

146 7 inhibited the tumor suppressive effects of calcitriol in cultured colorectal cancer cells and in mi

147 underpin the beneficial clinical effects of calcitriol in patients with SR asthma by directing the S

148 This selective production of calcitriol in proinflammatory myeloid cells has the pote

149 n shown to increase the antitumor effects of calcitriol in squamous cell carcinoma.

150 as lead compound a 20(R) gemini, related to calcitriol in terms of it is A-ring, where one side chai

151 tion factor, was enhanced in the presence of calcitriol in Th9 cells.

152 s increase was statistically significant for calcitriol in the time frame examined, but not statistic

153 19-norvitamin D(3) analogues proved equal to calcitriol in their ability to bind to the vitamin D rec

154 uring MAC differentiation and that in vitro, calcitriol increased differentiation of monocytes into M

155 We recently showed that calcitriol increases oxidative and inflammatory stress;

156 the single CD4(+) peptide, BDC2.5(mim), and calcitriol induce ChgA-specific CD4(+) T cells that regu

157 Calcitriol induced expression of miR-627, which down-reg

158 nimals and that was ascribed to the LOV- and calcitriol-induced immunomodulatory synergy.

159 to release calcitriol from the cell and that calcitriol inhibits Smo action and ciliary translocation

160 n D, 1alpha,25-dihydroxyvitamin D3 (1,25D3) (calcitriol), into the third ventricle of the brain impro

161 ical steps in the synthesis of the A-ring of calcitriol involved an asymmetric carbonyl-ene reaction

162 it has been known for a number of years that calcitriol is a potent inhibitor of adipogenesis in this

163 These data suggest calcitriol is a potent inhibitor of retinal neovasculari

164 Calcitriol is implicated in many cellular functions incl

165 As the half-life of calcitriol is short, we hypothesized that there would be

166 Although inappropriate tumoral secretion of calcitriol is typically associated with lymphomas and so

167 gic vitamin D receptor agonist, 1,25(OH)2D3 (calcitriol), is synthesized by the essential enzyme 25-h

168 mone (PTH); and is associated with decreased calcitriol levels independent of renal function, hyperph

169 the hypophosphatemia and inappropriately low calcitriol levels observed after kidney transplantation

170 of decreased calcitriol, but the effects on calcitriol levels of renal function itself and hyperphos

171 ssociated with estimated GFR (eGFR), whereas calcitriol levels were linearly associated with eGFR.

172 RRT resulted in normalization of calcium and calcitriol levels, strongly supporting the hypothesis of

173 pite high parathyroid hormone (PTH) and high calcitriol levels.

174 controlled the refractory hypercalcaemia and calcitriol levels.

175 showed hypercalcemia with markedly increased calcitriol levels.

176 ar mechanism by which the unliganded VDR and calcitriol-liganded VDR regulate adipogenesis.

177 After BDC2.5(mim)/calcitriol liposome administration, adoptive transfer of

178 After BDC2.5(mim)/calcitriol liposome treatment and expansion of ChgA-spec

179 These results indicate that calcitriol-mediated antiproliferative effects on TDEC ar

180 Transcriptomic analysis revealed significant calcitriol-mediated effects on both Ag presentation and

181 silencing of CYP24 contributes to selective calcitriol-mediated growth inhibition in endothelial cel

182 e were relatively resistant, suggesting that calcitriol-mediated growth inhibition on TDEC is VDR-dep

183 This effect was based on a calcitriol-mediated increase of IFN-alpha-induced gene e

184 se inhibitor 5-aza-2'-deoxycytidine restored calcitriol-mediated induction of CYP24, which led to los

185 e have unraveled the molecular mechanisms of calcitriol-mediated regulation of Th9 cell differentiati

186 In response to locally produced calcitriol, myeloid dendritic cells (DCs) migrated from

187 Patients randomized to calcitriol (n = 36) versus placebo (n = 31) had similar

188 In contrast, in vivo treatment with calcitriol of mice challenged for EAU impaired commitmen

189 Calcitriol ointment 3 microg per g was irradiated with 1

190 smission of ultraviolet A is reduced through calcitriol ointment and its vehicle by 17%-31% and 17%-4

191 Calcitriol ointment has been approved for the treatment

192 More than 90% of calcitriol ointment is degraded upon exposure to ultravi

193 iol and, conversely, to study the effects of calcitriol ointment on transmission of different forms o

194 When used in conjunction with phototherapy, calcitriol ointment should be applied after ultraviolet

195 d the effect of discontinuing alendronate or calcitriol on bone loss and biochemical markers of bone

196 The effects of calcitriol on expression of miR-627 and cell proliferati

197 In this study, we explored the effect of calcitriol on homeostatic (M-CSF, TGF-beta-treated) and

198 knock-down reversed the inhibitory effect of calcitriol on LEC tube formation, demonstrating how such

199 The effects of calcitriol on retinal EC proliferation, migration, and c

200 The influences of locally produced calcitriol on the migration of activated DCs from sites

201 is combination therapy with low dose IBN and calcitriol on top of calcium and vitamin D supplementati

202 of low dose parenteral ibandronate (IBN) and calcitriol on top of calcium and vitamin D supplementati

203 l (control group) or the vitamin D analogues calcitriol or 1,25-dihydroxy-16-ene-23-yne vitamin D(3)

204 Actual use of the active form of vitamin D (calcitriol or 1alpha,25-dihydroxyvitamin D(3)) to treat

205 Moreover calcitriol or calcitriol derivatives combined with ITZ m

206 itant with either intermittent doses of oral calcitriol or doxercalciferol for 8 mo, when bone biopsi

207 are severely vitamin D deficient or who lack calcitriol or its receptor.

208 asthma were subsequently randomized to oral calcitriol or placebo therapy, and identical studies wer

209 calcifediol or dihydroxycholecalciferols or calcitriol or vitamin D/aa[analogs & derivates] or ergoc

210 ant were randomized to calcium, calcium plus calcitriol, or placebo.

211 arian germ cell tumors, we present a case of calcitriol overproduction-induced hypercalcemia due to a

212 0.223 per person-year) among those receiving calcitriol (P<0.001).

213 mone (P<0.001) and a significant increase in calcitriol (P=0.02) were noted postengraftment.

214 mong those who switched from paricalcitol to calcitriol (P=0.04).

215 lices by mouse marrow cultures stimulated by calcitriol, parathyroid hormone, and basic-fibroblast gr

216 In contrast, levels of calcium, phosphorus, calcitriol, parathyroid hormone, or fibroblast growth fa

217 rming this indirect effect included elevated calcitriol, phosphorus, alkaline phosphatase, and recept

218 receptor (VDR) and its ligand 1,25-OH2-VD3 (calcitriol) play an essential role in mineral homeostasi

219 the cumulative dose of phosphate binders and calcitriol predicted abnormal vascular structure and fun

220 Calcitriol-pretreated tumors underwent enhanced apoptoti

221 blind study to determine whether calcium and calcitriol prevents posttransplant bone loss.

222 Moreover, the increased calcitriol produced in response to low-calcium diets sti

223 lcium levels, confirming the hypothesis of a calcitriol producing pancreatic neuroendocrine tumor.

224 rcalcaemia of underlying malignancy due to a calcitriol-producing pancreatic neuroendocrine tumor, re

225 els, strongly supporting the hypothesis of a calcitriol-producing pancreatic neuroendocrine tumor.

226 sphaturia on a per-nephron basis and inhibit calcitriol production, thereby contributing centrally to

227 Fibroblast growth factor (FGF) 23 inhibits calcitriol production, which could exacerbate calcium de

228 udies with paricalcitol and two studies with calcitriol) providing data for 688 patients were include

229 Calcitriol reduced IP-10 expression by MACs (p<0.0006),

230 Further, we confirmed that vitamin D (calcitriol) reduced calcification as measured by Alizari

231 y prostatic epithelial cells and showed that calcitriol regulated the expression of genes involved in

232 Together, we suggest that calcitriol represents a possible endogenous transmitter

233 Our data show that calcitriol represses the expression of BATF, a transcrip

234 The concentration of calcitriol required to inhibit retinal EC proliferation

235 The active form of vitamin D (calcitriol) restored the SLE MAC phenotype towards that

236 Treatment with calcitriol resulted in growth inhibition in TDEC express

237 At a lower concentration of calcitriol, retinal EC capillary morphogenesis in solubi

238 istration of the active vitamin D metabolite calcitriol reversed all these effects.

239 h the predominant hormone/peptide secreted), calcitriol secreting pancreatic neuroendocrine tumors ar

240 Calcitriol significantly diminished IL-9 secretion from

241 Calcitriol significantly repressed the mRNA and protein

242 orphological and biochemical (serum calcium, calcitriol) stabilization.

243 During the neonatal period, calcitriol-stimulated intestinal calcium absorption beco

244 It inhibits bone resorption by calcitriol-stimulated mouse marrow cultures.

245 After calcitriol stimulation, we identified 2776 genomic posit

246 Moreover calcitriol strongly synergizes with itraconazole (ITZ) i

247 se of routine vs. selective oral calcium and calcitriol supplementation found that routine supplement

248 that routine postoperative oral calcium and calcitriol supplementation results in lower rates of tet

249 The role of endogenous calcitriol synthesis for the regulation of IgE has not b

250 clastogenesis, and indirectly, by increasing calcitriol synthesis.

251 The combination of GH and calcitriol that is frequently used in children with rena

252 Calcitriol, the active form of vitamin D, in combination

253 the hypercalcemia is excessive production of calcitriol, the active form of vitamin D.

254 tially neutralizing the antitumor effects of calcitriol, the active form of vitamin D.

255 In this article, we report that calcitriol, the active form of vitamin D3, can be admini

256 Here, we demonstrate that calcitriol, the hormonally active form of vitamin D3, is

257 cium and phosphorus levels, as compared with calcitriol, the standard form of injectable vitamin D.

258 In contrast, in the absence of calcitriol, the unliganded VDR appears necessary for lip

259 In the presence of calcitriol, the VDR blocks adipogenesis by down-regulati

260 severe form of SH and the most resistant to calcitriol therapy, higher TGF-alpha activation of the E

261 or fed low-phosphate chow supplemented with calcitriol to maintain normophosphatemia in CKD.

262 rvival rate among patients who switched from calcitriol to paricalcitol was 73 percent, as compared w

263 r administration of 1,25-dihydroxyvitamin D (calcitriol) to critically ill patients with sepsis would

264 upplementing physiologic doses of vitamin D (calcitriol) to cultured HL cell lines and demonstrated i

265 Calcitriol-treated animals demonstrated a significant de

266 lar level of VEGF was similar in control and calcitriol-treated animals.

267 5-formylTHF was also significantly higher in calcitriol-treated Folr1 KO mice (15-fold), indicating a

268 Media from calcitriol-treated MACs more strongly attenuated TNFalph

269 Media from calcitriol-treated MACs significantly increased angiogen

270 scularization was significantly inhibited in calcitriol-treated mice.

271 Calcitriol-treated patients had higher cathelicidin (P =

272 ring the serum and urinary calcium levels in calcitriol-treated patients makes alendronate more attra

273 clinical response to oral glucocorticoids in calcitriol-treated patients with SR asthma.

274 ong paricalcitol-treated patients than among calcitriol-treated patients.

275 Neither SLC20A1 nor XPR1 were affected by calcitriol treatment and remained suppressed.

276 Calcitriol treatment attenuated PG-mediated functional r

277 ts and the effect on immunophenotype of oral calcitriol treatment because it has been previously show

278 ion of TNF-alpha in tumors preconditioned by calcitriol treatment before receiving ALA-PDT.

279 While calcitriol treatment did not decrease cell proliferation

280 of mutant KRAS-driven lung cancer cells, and calcitriol treatment increased CYP24A1 levels and tumor

281 ells in vitro, an effect further enhanced by calcitriol treatment of SLE MACs.

282 Cells incubated with calcitriol under calcifying conditions specifically main

283 ism, and the absence of hypercalcemia before calcitriol use and then were matched by age and estimate

284 In conclusion, oral calcitriol use is associated with lower mortality in non

285 roid hormone, calcium, and phosphorous, oral calcitriol use was associated with a 26% lower risk for

286 Calcitriol use was associated with a greater risk for hy

287 We evaluated associations of oral calcitriol use with mortality and dialysis dependence in

288 Incident calcitriol users and nonusers were selected on the basis

289 rinary kidney injury markers were similar in calcitriol- versus placebo-treated patients (P > 0.05 fo

290 mulated in the presence of dexamethasone and calcitriol (vitamin D3).

291 When dietary phosphorus was restricted and calcitriol was administered in the CKD low-phosphate/cal

292 Calcitriol was associated with a higher risk of hypercal

293 Responsiveness to calcitriol was essential to promote the trafficking of m

294 The A-ring (Z)-dienol of calcitriol was synthesized in 12 steps from 3-(tert-buty

295 ith supplementation (calcium, magnesium, and calcitriol) was more effective than supplementation alon

296 response to avoid a subsequent reduction in calcitriol, which could exacerbate hypocalcemia.

297 cholesterol was observed with an increase in calcitriol, which is synthesized from a cholesterol deri

298 inflammatory stress; moreover, inhibition of calcitriol with high-calcium diets decreased both adipos

299 The association of calcitriol with improved survival was not statistically

300 The combination of calcitriol with nonsteroidal anti-inflammatory drugs (NS

301 posed to bioactive 1,25-dihydroxyvitamin D3 (calcitriol) with or without IFN-alpha.